NYSE:NGVT - Ingevity Stock Price, Forecast & News

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity Corp (NYSE:NGVT) released its earnings results on Wednesday, October, 23rd. The company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.04. The company had revenue of $359.90 million for the quarter, compared to analysts' expectations of $365.44 million. Ingevity had a net margin of 14.31% and a return on equity of 53.69%. The firm's revenue was up 15.6% compared to the same quarter last year. During the same quarter last year, the business earned $1.16 EPS. View Ingevity's Earnings History.

Ingevity is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Ingevity.

Ingevity issued an update on its FY 2019 earnings guidance on Wednesday, October, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.28-1.3 billion, compared to the consensus revenue estimate of $1.33 billion.

8 equities research analysts have issued 1 year price targets for Ingevity's shares. Their forecasts range from $96.00 to $130.00. On average, they anticipate Ingevity's share price to reach $110.38 in the next twelve months. This suggests a possible upside of 22.5% from the stock's current price. View Analyst Price Targets for Ingevity.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ingevity.

Media coverage about NGVT stock has been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ingevity earned a news sentiment score of -2.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Ingevity.

Ingevity saw a drop in short interest in November. As of November 15th, there was short interest totalling 982,000 shares, a drop of 8.2% from the October 31st total of 1,070,000 shares. Based on an average daily trading volume, of 310,700 shares, the days-to-cover ratio is presently 3.2 days. Approximately 2.4% of the shares of the stock are short sold. View Ingevity's Current Options Chain.

Some companies that are related to Ingevity include FMC (FMC), Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Balchem (BCPC), Olin (OLN), Chemours (CC), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM) and Innophos (IPHS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Costco Wholesale (COST), NVIDIA (NVDA), General Electric (GE), Quaker Chemical (KWR), Paypal (PYPL), Zebra Technologies (ZBRA), AbbVie (ABBV), Boeing (BA), Pfizer (PFE) and UnitedHealth Group (UNH).

Ingevity's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.17%), Massachusetts Financial Services Co. MA (2.43%), Chilton Investment Co. LLC (1.56%), Rice Hall James & Associates LLC (1.17%), Ardevora Asset Management LLP (0.75%) and Copper Rock Capital Partners LLC (0.59%). Company insiders that own Ingevity stock include John C Fortson, Katherine Pryor Burgeson and Phillip John Platt. View Institutional Ownership Trends for Ingevity.

NGVT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Chilton Investment Co. LLC, Millennium Management LLC, Calamos Advisors LLC, Copper Rock Capital Partners LLC, Pictet Asset Management Ltd., Chartwell Investment Partners LLC and Kornitzer Capital Management Inc. KS. Company insiders that have sold Ingevity company stock in the last year include John C Fortson, Katherine Pryor Burgeson and Phillip John Platt. View Insider Buying and Selling for Ingevity.

NGVT stock was purchased by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Stifel Financial Corp, Massachusetts Financial Services Co. MA, Rice Hall James & Associates LLC, Tygh Capital Management Inc., Squarepoint Ops LLC, Russell Investments Group Ltd. and Eagle Asset Management Inc.. View Insider Buying and Selling for Ingevity.

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NGVT stock can currently be purchased for approximately $90.13.

Ingevity has a market capitalization of $3.77 billion and generates $1.13 billion in revenue each year. The company earns $169.10 million in net income (profit) each year or $4.13 on an earnings per share basis. Ingevity employs 1,750 workers across the globe.View Additional Information About Ingevity.

The official website for Ingevity is http://www.ingevity.com/.

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]